BioAtla Inc (BCAB)
2.67
-0.43
(-13.87%)
USD |
NASDAQ |
May 20, 11:16
BioAtla Enterprise Value: 55.54M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 55.54M |
| May 16, 2024 | 68.53M |
| May 15, 2024 | 63.72M |
| May 14, 2024 | 44.95M |
| May 13, 2024 | 46.40M |
| May 10, 2024 | 49.76M |
| May 09, 2024 | 59.36M |
| May 08, 2024 | 69.94M |
| May 07, 2024 | 68.02M |
| May 06, 2024 | 71.87M |
| May 03, 2024 | 75.72M |
| May 02, 2024 | 71.39M |
| May 01, 2024 | 81.49M |
| April 30, 2024 | 27.85M |
| April 29, 2024 | 43.48M |
| April 26, 2024 | 41.56M |
| April 25, 2024 | 27.61M |
| April 24, 2024 | 32.42M |
| April 23, 2024 | 27.13M |
| April 22, 2024 | 24.24M |
| April 19, 2024 | 20.63M |
| April 18, 2024 | 36.27M |
| April 17, 2024 | 41.08M |
| April 16, 2024 | 45.65M |
| April 15, 2024 | 56.95M |
| Date | Value |
|---|---|
| April 12, 2024 | 69.91M |
| April 11, 2024 | 80.53M |
| April 10, 2024 | 75.72M |
| April 09, 2024 | 91.11M |
| April 08, 2024 | 103.62M |
| April 05, 2024 | 102.17M |
| April 04, 2024 | 107.95M |
| April 03, 2024 | 97.36M |
| April 02, 2024 | 88.70M |
| April 01, 2024 | 82.45M |
| March 28, 2024 | 53.98M |
| March 27, 2024 | 54.94M |
| March 26, 2024 | 33.30M |
| March 25, 2024 | 0.5943M |
| March 22, 2024 | 4.442M |
| March 21, 2024 | 4.396M |
| March 20, 2024 | 2.954M |
| March 19, 2024 | 6.800M |
| March 18, 2024 | 1.031M |
| March 15, 2024 | 5.838M |
| March 14, 2024 | 3.194M |
| March 13, 2024 | 11.37M |
| March 12, 2024 | 13.05M |
| March 11, 2024 | 25.55M |
| March 08, 2024 | 21.70M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-139.74M
Minimum
May 24 2022
2.149B
Maximum
Mar 18 2021
351.60M
Average
27.73M
Median
Enterprise Value Benchmarks
| Marinus Pharmaceuticals Inc | 33.28M |
| Equillium Inc | 22.71M |
| Poseida Therapeutics Inc | 169.34M |
| Biomea Fusion Inc | 295.04M |
| Candel Therapeutics Inc | 336.07M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.23M |
| Total Expenses (Quarterly) | 24.46M |
| EPS Diluted (Quarterly) | -0.48 |
| Earnings Yield | -93.26% |
| Normalized Earnings Yield | -82.68 |